3) Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002 120:714-20. discussion 829-30.
4) Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol 1983;118:166-91.
5) Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open Ophthalmol J 2010;4:52-9.
7) Bucolo C, Platania CB, Reibaldi M, et al. Controversies in glaucoma: current medical treatment and drug development. Curr Pharm Des 2015;21:4673-81.
8) Bucolo C, Salomone S, Drago F, et al. Pharmacological management of ocular hypertension: current approaches and future prospective. Curr Opin Pharmacol 2013;13:50-5.
14) Futakuchi A, Inoue T, Wei FY, et al. YAP/TAZ are essential for TGF-β2-mediated conjunctival fibrosis. Invest Ophthalmol Vis Sci 2018;59:3069-78.
15) Seibold LK, Sherwood MB, Kahook MY. Wound modulation after filtration surgery. Surv Ophthalmol 2012;57:530-50.
16) Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res 1994;59:723-7.
19) Fleenor DL, Shepard AR, Hellberg PE, et al. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci 2006;47:226-34.
21) Wang K, Read AT, Sulchek T, Ethier CR. Trabecular meshwork stiffness in glaucoma. Exp Eye Res 2017;158:3-12.
24) Huang S, Liu Z, Qian X, et al. YAP/TAZ promote fibrotic activity in human trabecular meshwork cells by sensing cytoskeleton structure alternation. Chemosensors 2022;10:235.
26) Taurone S, Ripandelli G, Pacella E, et al. Potential regulatory molecules in the human trabecular meshwork of patients with glaucoma: immunohistochemical profile of a number of inflammatory cytokines. Mol Med Rep 2015;11:1384-90.
27) Takeuchi K, Nakazawa M, Ebina Y. Effects of trehalose on VEGFstimulated angiogenesis and myofibroblast proliferation: implications for glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2011;52:6987-93.
28) Kuiper EJ, Hughes JM, Van Geest RJ, et al. Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Invest Ophthalmol Vis Sci 2007;48:4267-76.
31) Nishio M, Sugimachi K, Goto H, et al. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1bdeficient mice. Proc Natl Acad Sci U S A 2016;113:E71-80.
34) Elaimy AL, Mercurio AM. Convergence of VEGF and YAP/TAZ signaling: implications for angiogenesis and cancer biology. Sci Signal 2018 11:e. aau1165.
35) Wang X, Freire Valls A, Schermann G, et al. YAP/TAZ orchestrate VEGF signaling during developmental angiogenesis. Dev Cell 2017;42:462-78.e7.
40) Reggiani F, Gobbi G, Ciarrocchi A, Sancisi V. YAP and TAZ are not identical twins. Trends Biochem Sci 2021;46:154-68.
42) Wu Y, Chen W, Guo M, et al. Effects of transforming growth factor-β2 on myocilin expression and secretion in human primary cultured trabecular meshwork cells. Int J Clin Exp Pathol 2014;7:4827-36.